Dipeptidyl peptidase-4 inhibitors (DPP-4i) have been available for treating T2DM owing to their good safety profile and tolerability, as well as their efficacy in improving glycemic control [7]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.